{"schema_version":"1.0","type":"article","title":"太陽製藥、梯瓦製藥 與 全球學名藥廠的轉型焦慮","url":"https://drugnews.com.tw/articles/2026-05-27-generic-pharma-transformation-anxiety.html","markdown_url":"https://drugnews.com.tw/articles/2026-05-27-generic-pharma-transformation-anxiety.md","lang":"zh-Hant","date":"2026-05-27","publish_at":"2026-05-27T10:30:00+08:00","updated_at":"2026-05-27","category":"商業分析系列","topic":"公司研究","tags":["太陽製藥","梯瓦製藥","學名藥","轉型","製藥巨頭系列"],"summary":"全球學名藥巨頭面對價格壓力與成長瓶頸，轉型重點從傳統製造規模走向特殊學名藥、創新藥與更高門檻產品。","key_points":[],"facts":[],"sections":["💊 純粹的學名藥巨頭，不存在了","01｜Sun Pharma 為什麼要花 117.5 億美元買 Organon？","02｜豪賭背後，是學名藥公司的成長焦慮","03｜梯瓦製藥 （Teva） 的重生：從學名藥之王，轉向創新與專科藥品牌","04｜👁️ Viatris、Sandoz 也在做同一件事，只是路徑不同","05｜專利懸崖不是學名藥巨頭的保證，而是重新洗牌的開始","06｜這對台灣藥廠是警訊，也是機會","07｜📌 台灣不能只把學名藥當防守型產業","08｜學名藥的終局，不是低價，而是高門檻","結語｜🌊 學名藥巨頭正在上岸，台灣藥廠也該重新定位自己"],"references":[{"title":"[0]: 各公司官網＆公開資料","source":"","date":"","url":""},{"title":"[1]:","source":"","date":"","url":""},{"title":"Sun Pharma signs Definitive Agreement to Acquire Organon","source":"Organon","date":"","url":""},{"title":"Organon stockholders to receive US$ 14.00 per share in cash The deal values Organon at EV of US$ 11.75 billion Combined Business leverages complementary portfolios and global scale for sustained long‑term value creation Sun Pharmaceutical Industries Limit","source":"","date":"","url":""},{"title":"www.organon.com","source":"","date":"","url":""},{"title":"\"Sun Pharma signs Definitive Agreement to Acquire Organon","source":"Organon\"","date":"","url":""},{"title":"[2]:","source":"","date":"","url":""},{"title":"reuters.com","source":"","date":"","url":""},{"title":"https://www.reuters.com/business/healthcare-pharmaceuticals/sun-pharma-acquire-organon-1175-bln-all-cash-deal-2026-04-27/","source":"","date":"","url":"https://www.reuters.com/business/healthcare-pharmaceuticals/sun-pharma-acquire-organon-1175-bln-all-cash-deal-2026-04-27/"},{"title":"www.reuters.com","source":"","date":"","url":""},{"title":"\"Sun Pharma to buy US drugmaker Organon for $11.75 billion in India's largest pharma deal","source":"Reuters\"","date":"","url":""},{"title":"[3]:","source":"","date":"","url":""},{"title":"www.sec.gov","source":"","date":"","url":""},{"title":"https://www.sec.gov/Archives/edgar/data/1821825/000110465925108740/tm2530588d2_10qa.htm","source":"","date":"","url":"https://www.sec.gov/Archives/edgar/data/1821825/000110465925108740/tm2530588d2_10qa.htm"},{"title":"www.sec.gov","source":"","date":"","url":""},{"title":"[4]:","source":"","date":"","url":""},{"title":"Teva Pharmaceutical Industries Ltd. - Teva Innovative Portfolio and Consistent Execution of Pivot to Growth Strategy Deliver Third Consecutive Year of Growth; Pipeline Positioned to Unlock Significant Value Potential","source":"","date":"","url":""},{"title":"Teva delivers 3 consecutive years of growth - 2025 revenues of $17.3 billion, an increase of 4% year-over-year (YoY) in U.S. dollars, or 3% in local currency (LC) terms, compared to 2024. Excluding Japan BV, revenues increased 5% YoY in LC. Key Innovative","source":"","date":"","url":""},{"title":"ir.tevapharm.com","source":"","date":"","url":""},{"title":"\"","source":"","date":"","url":""},{"title":"Teva Pharmaceutical Industries Ltd. - Teva Innovative Portfolio and Consistent Execution of Pivot to Growth Strategy Deliver Third Consecutive Year of Growth; Pipeline Positioned to Unlock Significant Value Potential\"","source":"","date":"","url":""},{"title":"[5]:","source":"","date":"","url":""},{"title":"YouTube icon","source":"","date":"","url":""},{"title":"https://www.tevausa.com/news-and-media/press-releases/teva-reaffirms-pivot-to-growth-strategy-progress-with-launch-of-acceleration-phase-at-2025-innovation-a/","source":"","date":"","url":"https://www.tevausa.com/news-and-media/press-releases/teva-reaffirms-pivot-to-growth-strategy-progress-with-launch-of-acceleration-phase-at-2025-innovation-a/"},{"title":"www.tevausa.com","source":"","date":"","url":""},{"title":"\"Teva Reaffirms “Pivot to Growth” Strategy Progress with Launch of Acceleration Phase at 2025 Innovation a\"","source":"","date":"","url":""},{"title":"[6]:","source":"","date":"","url":""},{"title":"Teva Pharmaceutical Industries Ltd. - Teva Pharmaceuticals Submits New Drug Application to FDA for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults","source":"","date":"","url":""},{"title":"Olanzapine long-acting injectable (LAI) has the potential to offer the efficacy of olanzapine in a once-monthly, subcutaneous formulation, for a broad patient population 1 Olanzapine LAI is designed to help support real-world adherence and improved stabil","source":"","date":"","url":""},{"title":"ir.tevapharm.com","source":"","date":"","url":""}],"images":[{"alt":"Dcard 原圖：太陽製藥、梯瓦製藥 與 全球學名藥廠的轉型焦慮","url":"https://drugnews.com.tw/assets/articles/generic-pharma-transformation-anxiety/dcard-01.webp"},{"alt":"Dcard 原圖：太陽製藥、梯瓦製藥 與 全球學名藥廠的轉型焦慮","url":"https://drugnews.com.tw/assets/articles/generic-pharma-transformation-anxiety/dcard-02.png"},{"alt":"Dcard 原圖：太陽製藥、梯瓦製藥 與 全球學名藥廠的轉型焦慮","url":"https://drugnews.com.tw/assets/articles/generic-pharma-transformation-anxiety/dcard-03.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/generic-pharma-transformation-anxiety/dcard-01.webp","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-05-27）。太陽製藥、梯瓦製藥 與 全球學名藥廠的轉型焦慮。https://drugnews.com.tw/articles/2026-05-27-generic-pharma-transformation-anxiety.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-05-27-generic-pharma-transformation-anxiety-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}